Annika Strandhäll is no longer a government minister, Minister for Social Security
Ann Linde is Minister for Foreign Affairs from September 10, 2019
This content was published in the period between
The Swedish Government strongly criticizes the Commission’s EMA assessment in a letter today
The Minister for Health and Social Affairs Annika Strandhäll and the Minister for EU Affairs and Trade Ann Linde criticize the assessment in a letter today to the Commission with clarifying comments on the Swedish bid. The ministers conclude that this has not been a serious part of the process.
– We strongly disagree to the non-objective criteria within the EMA-bid process. This process has to have one objective and nothing else; patient safety for more than 500 million people living in the EU. That has to be the standards for the EU assessment and the vote of the member states and nothing else, says minister Strandhäll.
In short, the technical assessment states that the Swedish bid "does not meet EMA requirements", but Sweden more than meets all the specified criteria.
The bid states that Sweden offers the EMA a choice of secure premises in Stockholm, giving the EMA the opportunity to influence the design of the building such that it suits the requirements and needs of the Agency and that detailed plans for the whole relocation process will be drawn up in close cooperation with the EMA.
– This is the first common decision for EU 27 after the British referendum on the exit from the EU. It is therefore important that both the process and decisions are fair and objective, says Ann Linde, Minister for EU Affairs and Trade.
It is the Swedish Government's sincere hope and expectation that the Commission will continue to work for a transparent process based on objective criteria, and to this end acknowledge the correct and verifiable facts provided in the Swedish bid.
On 30 September, the Commission published its assessment, including a technical assessment performed by the agency itself, of the bids submitted for the relocation of the European Medicines Agency (EMA). The Commission's general assessment summary of Sweden's bid is correct; however, the technical assessment conducted by the EMA omits and misinterprets some of the information Sweden have provided.